Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of intravenous ulimorelin versus metoclopramide for enteral feeding intolerance in mechanically ventilated ICU patients
NL-OMON47313Phase 2Not yet recruiting
- Sponsor
- Lyric Pharmaceuticals
- Start
- Nov 2016
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ulimorelin in enteral feeding intolerance (EFI) (2 arms), sponsored by Lyric Pharmaceuticals. Primary endpoint: Primary efficacy endpoint. Planned start Nov 2016; status: not yet recruiting.
02
Drugs
ulimorelin
03
Conditions
enteral feeding intolerance (EFI)
Beyond the preview
Go deeper on NL-OMON47313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47313.